CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the“Company”), a clinical-stage company developing innovative drug therapies for the treatment of ...

In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), Oncolytics's flagship pelareorep, an intravenously ...

Is Pola-R-CHP a suitable standard for all or should the lack of survival benefit and differential subgroup responses give pause in treating all patients who qualify?

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

Lecture Methodological and Statistical Topics in Randomized Controlled Clinical Trials Claudia Caminha Escosteguy Rio de Janeiro, RJ - Brazil Among research methods, randomized controlled clinical ...

The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

NIH budget cuts are threatening key medical research programs, shrinking training grants, and leaving young researchers ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...